Pharmacogenomics Platforms Market is expected to reach USD 10.1 billion by 2031

Pharmacogenomics Platforms Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the pharmacogenomics platforms market will expand from USD 6.1 billion in 2026 to USD 10.1 billion in 2031 at a CAGR of 10.6% during the forecast period.

The worldwide Pharmacogenomics Platforms Market is becoming an essential part of precision medicine, owing to the increased requirement for tailoring drug therapies based on one's genetic makeup and minimizing the incidence of adverse drug reactions in the treatment of complex diseases. Health care facilities and drug manufacturing companies are progressively harnessing pharmacogenomics tools to enhance the effectiveness of therapies, speed up the discovery of biomarkers, and facilitate the development of targeted drugs, especially in the fields of oncology, cardiology, neurology, and psychiatry. In addition, the market is majorly supported by the rapid evolution of next-generation sequencing (NGS), PCR-based diagnostics, microarray technologies, and cloud-enabled bioinformatics platforms that enable genomic interpretation in a quicker and more economical manner.

Request a free sample copy or view the report summary: Pharmacogenomics Platforms Market Report

Pharmacogenomics Platforms Market Report Highlights

• Next-Generation Sequencing (NGS) is anticipated to be the most rapidly expanding technology component of the Pharmacogenomics Platforms Market because it can deliver a thorough genomic analysis that is both accurate and scalable. This technology is being widely applied in precision medicine, biomarker discovery, and companion diagnostics, especially in cancer and rare disease research. Decreasing costs of sequencing, the use of AI-driven genomic analytics, and increased utilization of multi-gene test panels are driving the growth of NGS platform demand in clinical and research environments.

• Among the therapeutic areas, oncology is expected to lead in growth, as the use of pharmacogenomics for targeted cancer therapies and personalized treatment planning keeps rising. To identify mutations, optimize drug selection, and improve treatment outcomes in cancer patients, drug companies and healthcare providers are increasingly depending on genomic profiling. The segment is getting a boost all over the world from increased spending on precision oncology programs and companion diagnostics.

• Among application segments, Personalized Medicine is expected to grow at the fastest pace since healthcare systems will significantly move to treatment methods tailored individually based on genetic profiles. Pharmacogenomics platforms quite effectively predict the drug response, reduce the risk of side effects, and enhance the therapeutic outcomes. Besides, the increasing incorporation of AI-powered clinical decision support tools and precision medicine campaigns is collectively contributing to the increased usage in hospitals, diagnostic labs, and pharmaceutical companies.

• Asia-Pacific is the fastest-growing regional market due to increasing healthcare digitization, the expansion of precision medicine programs, and the growing government support for genomic sequencing initiatives in China, India, Japan, and South Korea.

Pharmacogenomics Platforms Market Growth Drivers and Restraints

Growth Drivers:

• Rising Adoption of Personalized Medicine: Pharmacogenomics platforms assist doctors in determining an individual's drug metabolism, allowing for more accurate drug selection and dosage optimization. Such a method not only enhances the effectiveness of a therapy but also diminishes the risks of drug side effects and additional healthcare expenses.

• Technological Advancements in Genomic Sequencing and AI Integration: Rapid technological progress in next-generation sequencing (NGS), PCR technologies, bioinformatics software, and AI-driven genomic analytics is significantly driving market growth. Advanced sequencing technologies offer faster turnaround times, higher throughput, and lower operational costs compared to traditional genetic testing methods.

Restraints:

• High Costs of Genomic Testing and Platform Implementation: Though there have been great technical improvements, one of the biggest reasons pharmacogenomics has not been adopted more widely is the very high cost of testing and setting up the platform.

Pharmacogenomics Platforms Market Key Development

• Collaboration: In January 2026, Novo Genomics and PGxAI teamed up to introduce AI-based pharmacogenome research in Saudi Arabia. Leveraging Novo Genomics' lab in Saudi Arabia and PGxAI's powerful analysis tools, the partnership will, among others, shorten the time of results, improve data control, and overall expand patients' reach to precision medicine within healthcare facilities across the Kingdom.

• Product Launch: In September 2025, Quest Diagnostics launched a pharmacogenomic commercial laboratory test service to better serve healthcare providers by allowing them to understand how specific medications may interact with a patient's unique genetic profile. This new service will use advanced technology to support doctors in determining the optimal choice of medication for each individual.

Pharmacogenomics Platforms Market Segmentation

Knowledge Sourcing Intelligence has segmented the pharmacogenomics platforms market based on therapeutic area, technology, application, and region:

Pharmacogenomics Platforms Market, By Technology

• Next-Generation Sequencing (NGS)

• Polymerase Chain Reaction (PCR)

• Microarray Technology

• Mass Spectrometry

• Others

Pharmacogenomics Platforms Market, By Therapeutic Area

• Oncology

• Cardiology

• Neurology

• Psychiatry

• Infectious Diseases

• Others

Pharmacogenomics Platforms Market, By Application

• Drug Discovery & Development

• Clinical Diagnostics

• Personalized Medicine

• Research Applications

• Companion Diagnostics

Pharmacogenomics Platforms Market, By Region

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Pharmacogenomics Platforms Market Key Players

• Thermo Fisher Scientific

• Illumina, Inc.

• F. Hoffmann-La Roche Ltd

• QIAGEN N.V.

• Agilent Technologies, Inc.

• GE HealthCare

• Abbott Laboratories

• Bio-Rad Laboratories

• Myriad Genetics, Inc.

• Foundation Medicine, Inc.

• PerkinElmer, Inc.